Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05478486 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Assessment of Safety, Tolerability and PK Profile of MSP008-22 in Patients With Advanced Solid Tumours

Start date: September 1, 2022
Phase: Phase 1
Study type: Interventional

This is the 'first-in-human' clinical trial of the Investigational Medicinal Product (IMP), Tablet formulation for Oral dosing of MSP008-22, a molecule (new chemical entity) with anticancer properties.

NCT ID: NCT05474859 Not yet recruiting - Clinical trials for Advanced Solid Tumor

Subjects With Advanced or Metastatic Solid Tumor Malignancies

Start date: March 2024
Phase: Phase 1
Study type: Interventional

This study is an open-label, Phase 1, multicenter, continuous dose escalation study of XT-0528 in adult subjects with Advanced or Metastatic Solid Tumor Malignancies. The study will consist of 4 periods: Screening Period (up to 28 days prior to Cycle 1 Day 1) Safety Run-in Period (Cycle 1; continuous dosing on Days 1-21 of 28-day cycle) Continuous Dosing Period (Cycle 2 and beyond; continuous dosing on Days 1-28 of 28-day cycle) Safety Follow-up Period (30 days post-last dose).

NCT ID: NCT05468190 Recruiting - Ovarian Cancer Clinical Trials

A Clinical Research About CD70-positive Advanced/Metastatic Solid Tumors Treated by CD70-targeted CAR-T

Start date: July 17, 2022
Phase: Phase 1
Study type: Interventional

As a phase I clinical research,this study plans to evaluate the safety and tolerability of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion patterns.

NCT ID: NCT05465590 Withdrawn - Breast Cancer Clinical Trials

A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer

Start date: December 2022
Phase: Early Phase 1
Study type: Interventional

The study will evaluate the pharmacokinetics (PK) and safety of a single intravenous (IV) dose of 0.3 mg/kg MB1707 in patients with advanced cancers.

NCT ID: NCT05463432 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of HR19024 in Subjects With Advanced Solid Tumor

Start date: August 10, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the safety,tolerability,pharmacokinetic characteristics and preliminary efficacy of HR19024 injection in the treatment of advanced solid tumor

NCT ID: NCT05462717 Active, not recruiting - Clinical trials for Advanced Solid Tumor

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Start date: September 19, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.

NCT ID: NCT05461287 Recruiting - Clinical trials for Advanced Solid Tumor

Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors

Start date: September 30, 2022
Phase: Phase 1
Study type: Interventional

This is an open label, phase 1 clinical study to evaluate the safety, tolerability, dose limiting toxicities (DLTs), maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended phase 2 dose (RP2D) of QLS31904 q2w/q3w intravenous use in patients with advanced solid tumors. Additional objectives are to characterise pharmacokinetics and pharmacodynamics, and to evaluate efficacy signals. This study is consisted of phase Ia (Dose Escalation) and phase Ib (Dose Expansion). Phase Ib will further explore QLS31904 in selected patients populations based on data from phase Ia. The Phase Ib objectives, endpoints and design will be specified in a study protocol amendment after availability of phase Ia results.

NCT ID: NCT05451602 Recruiting - Clinical trials for Advanced Solid Tumor

HEC169096 in Participants With Advanced Solid Tumors

Start date: October 21, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

An Open, Multi-Center Phase I/II Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetic Characteristics And Effectiveness Of HEC169096 In Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors.

NCT ID: NCT05443126 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of EP0031 in Patients With Advanced RET-altered Malignancies

Start date: September 30, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to assess the safety, side effects and effectiveness of EP0031 in patients with advanced RET-altered malignancies

NCT ID: NCT05438329 Recruiting - Clinical trials for Advanced Solid Tumor

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Start date: July 19, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1305/BNT325 in subjects with advanced solid tumors.